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Protocol
AbstrACt
Introduction Total mesorectal excision (TME) is the 
highly effective standard treatment for rectal cancer 
but is associated with significant morbidity and may be 
overtreatment for low-risk cancers. This study is designed 
to determine the feasibility of international recruitment 
in a study comparing organ-saving approaches versus 
standard TME surgery.
Methods and analysis STAR-TREC trial is a multicentre 
international randomised, three-arm parallel, phase II 
feasibility study in patients with  
biopsy-proven adenocarcinoma of the rectum. The trial 
is coordinated from Birmingham, UK with national hubs 
in Radboudumc (the Netherlands) and Odense University 
Hospital Svendborg UMC (Denmark). Patients with rectal 
cancer, staged by CT and MRI as ≤cT3b (up to 5 mm of 
extramural spread) N0 M0 can be included. Patients will 
be randomised to either standard TME surgery (control), 
organ-saving treatment using long-course concurrent 
chemoradiation or organ-saving treatment using  
short-course radiotherapy. For patients treated with 
an organ-saving strategy, clinical response to (chemo)
radiotherapy determines the next treatment step. An active 
surveillance regime will be performed in the case of a 
complete clinical regression. In the case of incomplete 
clinical regression, patients will proceed to local excision 
using an optimised platform such as transanal endoscopic 
microsurgery or other transanal techniques (eg, transanal 
endoscopic operation or transanal minimally invasive 
surgery). The primary endpoint of this phase II study is 
to demonstrate sufficient international recruitment in 
order to sustain a phase III study incorporating pelvic 
failure as the primary endpoint. Success in phase II is 
defined as randomisation of at least four cases per month 
internationally in year 1, rising to at least six cases per 
month internationally during year 2.
Ethics and dissemination The medical ethical 
committees of all the participating countries have 
approved the study protocol. Results of the primary and 
secondary endpoints will be submitted for publication in 
peer-reviewed journals.
trial registration number ISRCTN14240288, 20 October 
2016. NCT02945566; Pre-results, October 2016.
strengths and limitations of this study
 ► This phase II study is the first study to randomise 
between the standard of care in early rectal cancer 
(ie, total mesorectal excision surgery) and two 
organ-saving strategies using (chemo)radiotherapy 
followed by selective transanal microsurgery.
 ► STAR-TREC study will show whether it is feasible 
to recruit enough patients for a consecutive 
international large, multicentre randomised phase 
III trial.
 ► The study design incorporates several adjustments 
in standard (chemo)radiation therapy protocols 
intended to reduce treatment-related side effects 
associated with organ-saving therapy.
 ► Clinical nodal staging of rectal cancer is rather 
unreliable and patients with false-negative nodal 
disease will be included in the study.
 ► Experience with clinical judgement of a complete 
response is difficult and needs to be monitored 
carefully with central reviewing during the study.
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IntroduCtIon
The introduction of bowel cancer screening is associ-
ated with a significant increase in the incidence of early-
stage rectal cancer.1 2 Total mesorectal excision (TME) 
surgery is an effective oncological treatment for early-
stage rectal cancer, only 2% and 12% of patients expe-
rience local or distant failure, respectively.3–5 However, 
standard surgery for rectal cancer requires permanent 
stoma formation in 10%–20% of cases and temporary 
stoma formation in 60%–70%.6 7 Many temporary stomas 
are not reversed.8 9 Furthermore, TME surgery is associ-
ated with major morbidity and mortality in a significant 
number of patients. Over 50% of all patients following 
TME surgery experience faecal incontinence, whereas 
urinary problems and sexual dysfunction are observed 
in 32%–80% of patients.10–14 Another complication 
following TME surgery is anastomotic bowel leakage 
which occurs in approximately 15% of patients.15 In 
addition, quality-of-life studies show that TME surgery 
is associated with persistently poor social role and body 
image.12 16–19 Mortality following TME surgery rises with 
age; the 6-month mortality following TME surgery is 
2.0%–4.6% for young patients with rectal cancer and 
9.0%–13.4% for elderly patients (aged >75 years).20–22 
There are concerns that TME surgery, which evolved to 
treat locally advanced, symptomatic tumours, may result 
in significant overtreatment of early screen-detected 
tumours. An organ-preserving strategy may generate 
significantly less morbidity without substantially compro-
mising oncological outcomes. Promising outcomes have 
been reported for (chemo)radiation therapy followed by 
watchful waiting or local excision. 
Habr-Gama’s group have notably published a watchful 
waiting approach to rectal cancer. Of 265 patients with 
predominantly T3 rectal cancer treated with chemoradi-
ation therapy (CRT), 71 patients (27%) had a complete 
clinical response (cCR).23 24 These patients did not have 
surgery and after a mean follow-up of 57 months (range: 
18–156), only two patients developed local recurrence, 
one of which was successfully salvaged. A Dutch group then 
prospectively selected patients with cCR for a watchful 
waiting strategy (n=21).25 After a mean follow-up 25 
months (±19 months), one patient had developed a local 
recurrence which was salvaged by surgery and all other 
patients were alive without disease. In 2015, the effect of 
a radiation boost after CRT was evaluated in a prospective 
observational Danish study. A watch and wait policy was 
possible in 40 out of 51 included patients.26 At 1 year, local 
recurrence occurred in 16% of 40 patients who initially 
showed a cCR. Rectal bleeding was relatively frequent in 
this study during follow-up perhaps relating to the higher 
radiotherapy doses that were used. However, these results 
which combine high cCR rates and low local recurrence 
rates have not been consistently replicated.27 28 Further-
more, CRT is associated with treatment-related morbidity 
and a mortality rate of 0.5%–1% should be considered.29
Another organ-saving treatment strategy is local exci-
sion instead of radical surgery. Early rectal tumours may 
be locally excised through the anus with low morbidity 
and mortality using transanal endoscopic microsurgery 
(TEM), allowing rectal-saving treatment.30 31 Morbidity 
and mortality after local excision are much lower than 
after major resection. Morbidity associated with TEM 
includes bowel perforation, (transitory) incontinence, 
wound infection and local pain.32–34 In a study of 5305 
patients with early-stage rectal cancer, 30-day mortality 
after local excision was found to be 0.5% compared with 
2.4% in patients undergoing major resection (P=0.008). 
Morbidity within 30 days of surgery was 4.4% in the local 
excision group versus 12.7% in the major resection group 
(P<0.001).34 However, the risk of non-radical resection 
after local excision is higher and the risks of leaving 
behind microscopic lymph node metastases are a poten-
tial cause of local failure.5 35 The incidence of lymph node 
metastasis ranges from 6% to 14% for T1 tumours, 17% 
to 23% for T2 tumours and 49% to 66% for T3 tumours.36
Combining radiotherapy with TEM could possibly 
lead to better outcomes because radiotherapy can effec-
tively treat microscopic mesorectal nodal metastases and 
contribute to tumour downsizing.37 38 However, limited 
prospective evidence currently exists to guide the use of 
radiotherapy and local excision as curative treatment for 
early rectal cancer. Lezoche et al randomised 100 patients 
with T2N0 rectal cancer to CRTfollowed by laparoscopic 
TME surgery or CRT and TEM with a 6–8 week interval 
to surgery.39 After a median follow-up of 9 years, local 
recurrence rates were 6% and 8% in the TME and TEM 
arms, respectively. In a trial of 89 patients with unfavour-
able cT1N0, cT2N0 or borderline cT2/3N0 tumours by 
Bujko et al, patients were given neoadjuvant treatment 
with short-course radiation therapy (SCRT) or CRT prior 
to delayed local excision.40 No further treatment was 
offered for good responders, whereas immediate TME 
surgery was recommended for all other patients. Good 
responders had a 2-year local recurrence rate of 10%. Of 
the poor responders, eight patients had a TME and none 
of this group had a recurrence, however, 18 declined or 
were unfit for TME, and this group had a 2-year local 
recurrence rate of 37%. This underlines that in high-risk 
or poor responding patients, neoadjuvant radiotherapy 
followed by local excision is inadequate treatment.
A study investigating chemoradiation therapy for rectal 
cancer in the distal rectum followed by organ-sparing tran-
sanal endoscopic microsurgery (CARTS) was a non-ran-
domised phase II study that evaluated CRT followed by 
TEM in 55 patients with stage T1–3N0 rectal cancer.41 
Clinical response was assessed 6–8 weeks after comple-
tion of CRT and TEM was performed. Organ saving was 
achieved in more than half of patients and 21 had ypT0 
disease. Radiotherapy consisted of 50 Gy in 25 fractions 
and capecitabine 825 mg/m2 two times per day was given 
for the same period 7 days per week. However, 42% of 
patients developed at least grade 3 toxicity and there 
were two toxicity-related deaths. A multicentre cohort 
study from the UK that employed SCRT with TEM after 
10 weeks demonstrated that 43/62 cases had either no or 
group.bmj.com on January 22, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Rombouts AJM, et al. BMJ Open 2017;7:e019474. doi:10.1136/bmjopen-2017-019474
Open Access
minimal residual disease following radiotherapy.42 None 
of these patients experienced short-term pelvic relapse 
and treatment-related toxicity was low. The ACOSOG 
Z6041 study, a single-arm phase II study, evaluated an 
oxaliplatin and capecitabine concurrent chemotherapy 
schedule combined with 54 Gy of pelvic radiotherapy 
followed by TEM for T2N0 rectal cancer.43 Both radio-
therapy and chemotherapy schedules required reduction 
during the study due to acute toxicity. Only 3 out of 79 
evaluable patients experienced local failure as first event. 
TREC is a phase II UK study evaluating the feasibility of 
randomising patients to receive either organ-saving treat-
ment with SCRT and TEM versus standard TME surgery. 
This study is due to report in 2017 having completed 
minimum 2-year follow-up.
In conclusion, several strategies can be followed to 
improve the quality of life of patients with rectal cancer 
by aiming for organ preservation. However, all data so far 
are derived from small phase II studies and many ques-
tions regarding the optimal radiotherapy schedule and 
the optimal timing of evaluation remain. In addition, 
prospective comparative data with radical surgery are 
not available. Therefore, there is an urgent need for a 
randomised phase III trial to establish the risks, compli-
cation rates and benefits of organ saving compared with 
standard radical surgery for early-stage rectal cancer. 
The aim of STAR-TREC study is to assess the feasibility of 
successfully recruiting to a large, multicentre randomised 
trial comparing radical surgery versus organ saving treat-
ment using (chemo)radiotherapy followed by selective 
transanal microsurgery.
MEthods And AnAlysIs
design
STAR-TREC trial is a multicentre international 
randomised, three-arm parallel study in patients with 
biopsy-proven adenocarcinoma of the rectum. The trial is 
coordinated from Birmingham, UK with national hubs in 
Radboudumc (the Netherlands) and Odense University 
Hospital Svendborg UMC (Denmark). Participants are 
currently being recruited and enrolled; the first patient 
was enrolled in July 2017.
The primary endpoints of STAR-TREC study (phase II) 
are defined as:
1. Year 1: Randomise at least four cases per month inter-
nationally (n=48).
2. Year 2: Randomise at least six cases per month inter-
nationally (n=72).
The secondary endpoints of this phase II trial are:
1. Year 1: Can one international partner procure inde-
pendent funding in year 1? Successful internation-
al collaboration will be necessary to deliver a future 
phase III study.
2. Year 1: Can one international partner open the study 
to recruit in year 1?
3. Efficacy of organ-preserving treatment arms on com-
pletion of phase II study: Is the organ-saving rate 
>50% at 12 months (following randomisation) in the 
experimental arms?
Additional outcome measures pertinent to a future 
phase III study examining the safety and efficacy 
of organ saving versus standard surgery will also be 
collected.
Safety
 ► accuracy of MRI in predicting STAR-TREC eligibility;
 ► 30-day and 6-month mortality;
 ► surgical morbidity;
 ► rate of tumour recurrence or regrowth within the 
bowel wall (experimental arm);
 ► rate of tumour recurrence within the mesorectum 
(experimental arm);
 ► rate of distant metastases;
 ► pelvic failure rate: expressed as a sum of the following: 
(1) unresectable pelvic tumour, (2) cases requiring 
beyond TME surgery or (3) tumour recurrence or 
regrowth ≤1 mm from the circumferential surgical 
margin after TME surgery. This outcome measure 
will be pivotal in challenging current clinical practice 
and it is our intention that it becomes the primary 
endpoint in phase III;
 ► bowel, bladder and sexual dysfunction (baseline and 
12, 24 months postrandomisation).
Efficacy
 ► proportion of patients with/without a stoma at 30 days 
and 1 year;
 ► histopathological assessment of tumour down-
staging following radiotherapy according to depth of 
tumour invasion and the incidence of other high-risk 
features in comparison to non-irradiated (control) 
group;
 ► proportion of patients identified by clinical and MRI 
assessment as suitable for active monitoring;
 ► conversion rates from organ saving to radical surgery;
 ► disease-free survival;
 ► quality of life (baseline and 12, 24 months 
postrandomisation);
 ► overall survival.
study population
This is a hospital-based study. Centre eligibility depends 
on a Radiotherapy Trials Quality Assurance which is a 
mixture of an approved departmental standard operating 
procedure and successful contouring of a case using the 
new principles of mesorectal irradiation. Candidates will 
generally be identified in the endoscopy suite following 
referral for: (1) the investigation of new bowel symptoms, 
(2) as part of a personal bowel surveillance programme 
or (3) through national bowel screening. Subjects will 
then be referred on to either a colorectal surgeon or the 
colorectal cancer multidisciplinary team (MDT) meeting. 
Eligibility will be confirmed at the MDT meeting. The 
main inclusion and exclusion criteria for the trial are 
summarised in table 1.
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study arms
Patients will be randomised to either standard TME 
surgery (control), organ-saving treatment using long-
course concurrent CRT or organ-saving treatment using 
SCRT (figure 1). Patients allocated to TME surgery will 
have a minimum of one abdominal CT scan and regular 
clinical follow-up will be made according to national 
guidelines. In the two organ-saving arms, response assess-
ment will take place at 11–13 weeks from the start of 
(chemo)radiotherapy and again at 16–20 weeks from 
start. Initial assessment at 11–13 weeks (MRI and endos-
copy) will identify a small proportion of cases where 
radiotherapy has had little or no impact on tumour 
dimensions. Non-responding patients will be advised 
to convert to standard TME surgery. Individuals whose 
tumours demonstrate a satisfactory response at this 
time point will be examined once again at 16–20 weeks 
(endoscopy) to determine if a cCR has occurred. It is 
anticipated that this interval between assessments will 
allow for additional tumour regression and resolution 
of acute radiotherapy reactions, facilitating more precise 
diagnosis of cCR. An active surveillance regime will be 
performed in the case of a cCR. In the case of incomplete 
clinical regression, patients will progress to local excision, 
see figure 1. Representative endoscopic images will be 
centrally reviewed during this feasibility stage to develop 
a consistent approach to interpretation of the clinical 
assessment.
All patients must be assigned to one of the three treat-
ment groups by week 20:
1. Poor response assessed at 11–13 weeks—patient rec-
ommended to convert to radical TME surgery.
2. cCR assessed at 16–20 weeks means that the bowel 
wall has reverted to normal and patients are treated 
by watchful waiting.
3. Clinically satisfactory, yet incomplete tumour response 
at 16–20 weeks, meaning a 50% or more reduction of 
tumour size and the presence of any residual mucosal 
or bowel wall abnormality suggestive of persisting tu-
mour, will prompt local excision by TEM.
treatment regimen for organ-saving strategies
Long-course CRT consists of capecitabine and is adminis-
tered at a dose of 825 mg/m2 two times per day on radio-
therapy days only. A total dose of 50 Gy will be applied to 
the primary tumour and surrounding mesorectum, in 25 
fractions of 2 Gy, 5 days per week.
SCRT consists of a total dose of 25 Gy, applied to the 
primary tumour and surrounding mesorectum in five 
fractions of 5 Gy, preferably on five consecutive days. 
Radiotherapy for organ preservation is primarily aimed 
at tumour downstaging and can therefore be restricted to 
the peritumoral area including the primary tumour and 
the mesorectum resulting in a significant reduction in the 
irradiated target volume.
randomisation
Patients will be randomised on a 1:1:1 basis between stan-
dard surgical treatment and organ-saving treatments. 
Randomisation will be provided by a computer-generated 
program at the University of Birmingham Clinical Trials 
Units. The randomisation program will use a minimisa-
tion procedure for the following variables:
1. MRI tumour staging (≤T3a N0 V0 and T3b N0 V0) 
(T3a: tumour extends <1 mm beyond muscularis 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Age >16 years (UK), age >18 years (Netherlands and Denmark) 1. MRI node positive*
2. Biopsy-proven adenocarcinoma of the rectum 2. MRI extramural invasion present*
3. MRI T1–3b N0 M0 rectal tumour 3. MRI-defined mucinous tumour
4. Multidisciplinary team meeting determines that the following 
treatment options are all reasonable and feasible:
a. TME surgery,
b. Chemoradiation therapy,
c. Short-course chemoradiation therapy
d. TEM
4. Mesorectal fascia threatened by tumour (≤1 mm on 
MRI)
5. Estimated creatinine clearance >50 mL/min 5. Maximum tumour diameter >40 mm; measured from 
everted edges on sagittal MRI
6. Anterior tumour location above the peritoneal reflection 
on MRI or endoscopic rectal ultrasound
7. No residual luminal tumour following endoscopic 
mucosal resection
8. Prior pelvic radiotherapy
9. Regional or distant metastases
*Defined by protocol guidelines.
TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.
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propria; T3b: tumour extends 1–5 mm beyond mus-
cularis propria)
2. country (UK, the Netherlands, Denmark).
Stratification and minimisation will be by T-stage to 
ensure that the more advanced tumours are equally repre-
sented across treatments; stratification and by country 
will be done to account for any bias arising from any 
possible differences in pretreatment MRI-based staging 
assessment.
To avoid any possibility of the treatment allocation 
becoming too predictable, a random factor will be 
included within the algorithm whereby for a propor-
tion of the allocations true randomisation will be imple-
mented rather than by using the minimisation allocation.
sample size
No power calculation is provided as the primary objec-
tive is to show feasibility of recruitment. The aim of the 
present trial is to include four to six patients per month 
in order to have a high enough randomisation rate to 
perform a phase III trial. For a phase III trial, the primary 
outcome would be 3-year pelvic failure. The null hypoth-
esis is that the increase in the rate of pelvic failure at 3 
years with organ preservation compared with standard 
surgery is less than 7% absolute difference. Prior data 
indicate that the pelvic recurrence rate in the radical 
TME group is 2%. If the true recurrence rate for patients 
in an experimental arm is 9% then, using 90% power and 
alpha=0.025 (to account for two treatment comparisons) 
would require 117 patients per treatment arm. Antici-
pating a 10% dropout rate, we would aim to randomise 
400 participants. The final decision for a phase III sample 
size will be taken from information gained during the 
feasibility study. Data of the phase II trial will be used for 
the phase III trial.
Figure 1 Flow chart of the inclusion, randomisation and management of the study subjects in STAR-TREC trial. APE, anterior 
perianal excision; CRT, chemoradiation therapy; LAR, low anterior resection; SCRT, short-course radiation therapy; TEM, 
transanal endoscopic microsurgery; TME, total mesorectal excision.
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data management
Case report forms (CRFs) can be entered online at http://
www. bctu. bham. ac. uk/ STAR- TREC. Authorised staff at 
sites will require an individual secure login username and 
password to access this online data entry system. Paper 
CRFs must be completed, signed/dated and returned 
to the National STAR-TREC Trial Office by the investi-
gator or an authorised member of the site research team. 
Data reported on each CRF should be consistent with the 
source data or the discrepancies should be explained. 
If information is not known, this must be clearly indi-
cated on the CRF. All missing and ambiguous data will be 
queried. All sections are to be completed.
Assessment of the health-related quality of life will be 
done after the patients have completed a series of ques-
tionnaires. The questionnaires European Organisation 
for Research and Treatment of Cancer Quality of life 
questionnaires for colorectal cancer quality of life ques-
tionnaire C30 and CR29 (EORTC QLQL), standardised 
questionnaire for use as a measure of health outcome 
(EQ-5D), Low Anterior Resection Syndrome (LARS) 
score and Patient-completed questionnaire for evaluating 
male/female lower urinary tract symptoms and impact on 
quality of life (ICIQ-MLUTS/ICIQ FLUTS) will be done 
at three time points, at baseline prior to treatment and at 
follow-up 12 and 24 months after the start of treatment.
All trial records must be archived and securely retained 
for at least 25 years. No documents will be destroyed without 
prior approval from the Sponsor, via the central STAR-
TREC trial office. On-site monitoring will be carried out as 
required following a risk assessment and as documented 
in the monitoring plan for each participating country. Any 
monitoring activities will be reported to the central STAR-
TREC office and any issues noted will be followed up to 
resolution. STAR-TREC will also be centrally monitored; 
however, additional on-site monitoring may occur if trig-
gered. Further information regarding data management is 
provided in the study protocol.
Ethics and dissemination
The trial will be performed in accordance with the recom-
mendations guiding physicians in biomedical research 
involving human subjects, adopted by the 18th World 
Medical Association General Assembly, Helsinki, Finland 
and stated in the respective participating countries laws 
governing human research, and Good Clinical Practice. 
The medical ethical committees of all the participating 
countries have approved the study protocol.
A meeting will be held after the end of the study to 
allow discussion of the main results among the collabo-
rators prior to publication. Results of the primary and 
secondary endpoints will be submitted for publication in 
peer-reviewed journals.
dIsCussIon
The TREC and CARTS groups have combined with 
colleagues in Denmark to design STAR-TREC study. Phase 
II data from TREC and CARTS justifies a randomised 
comparison of standard radical surgery versus organ-
saving treatment using either SCRT or CRT with selective 
use of transanal microsurgery based on a radiotherapy 
response assessment. Organ preservation is not standard 
treatment and testing the feasibility is important to deter-
mine the scale of randomised trial that can be performed. 
The phase II STAR-TREC study will evaluate the feasibility 
of accelerating recruitment to an international three-arm 
randomised trial.
The published literature supports use of (chemo)radio-
therapy and transanal microsurgery as an alternative to 
major surgery for curative treatment of early rectal cancer. 
To date, studies have recruited patients who were highly 
motivated to organ-preserving treatment. Broader patient 
populations are yet to be evaluated using these organ-
saving treatments. In addition, the long-term impact of 
organ-saving treatment after neoadjuvant treatment, 
on quality of life and, more importantly, oncological 
outcome is unknown. Therefore, these organ-preserving 
strategies should ideally be compared with radical TME 
surgery which represents the current standard of care for 
patients with rectal cancer. A randomised trial comparing 
organ-saving treatment with major surgery might be prac-
tice changing for the treatment of patients with early 
rectal cancer.
In addition, while it seems probable that a strategy 
of organ saving may produce substantial benefits over 
conventional radical surgery, the optimum organ-saving 
treatment schedule remains unclear. Phase II studies 
suggest that SCRT may have the lowest acute toxicity while 
CRT may achieve the highest cCR rates. Randomisation 
between these two strategies with the interval calculated 
from the start of (chemo)radiotherapy will give insight in 
the possible difference in efficacy in these early cancers. 
STAR-TREC is, therefore, an international, multicentre, 
randomised, phase II feasibility study comprising a 1:1:1 
randomisation for eligible subjects with early clinically 
localised rectal cancer.
While published data supports further evaluation of 
organ saving in patients with early-stage rectal cancer 
using either SCRT or CRT followed by transanal microsur-
gery, it has also become clear that not all patients require 
surgery. Watchful waiting after complete response is being 
investigated in patients already in need of CRT.24 26 37 
Other studies introduce (chemo)radiation therapy to the 
treatment regimen in order to facilitate organ preserva-
tion. Current techniques use either SCRT (five fractions 
of 5 Gy)40 42 or concurrent fluoropyridine-based CRT (25 
fractions of 1.8 or 2 Gy).38–40 42 Radiotherapy is routinely 
followed by TEM, to remove the portion of bowel wall 
affected by cancer. However, in a significant proportion of 
patients, there are no signs of residual tumour following 
radiotherapy. This is termed a cCR. These patients are 
likely overtreated by routine transanal microsurgery and 
therefore possibly subjected to unnecessary surgery-re-
lated morbidity. Therefore, patients with a cCR might be 
better served by a watchful waiting approach.44
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STAR-TREC study design incorporates several devel-
opmental steps, each intended to further reduce treat-
ment-related side effects associated with organ-preserving 
therapy:
1. Modification in the capecitabine dose from 825 mg/
m2 two times per day for 7 days per week used in 
CARTS to 825 mg/m2 two times per day for 5 days per 
week.
2. Use of a smaller radiotherapy volume incorporating 
only the primary tumour, rectal wall and mesorectum.
3. Use of a two-step clinical response assessment tool 
following (chemo)radiation so that (1) poor respond-
ers are converted to radical TME surgery at the earli-
est opportunity while (2) good responders are given 
more time to determine if they reach cCR and may 
avoid transanal microsurgery.
4. Selective use of transanal microsurgery/TEM for re-
sidual mucosal or bowel wall abnormality suggestive 
of persisting cancer.
5. Objective comparison of the efficacy of CRT versus 
SCRT with similar intervals between start of radiother-
apy and evaluation.
To date, no significant differences are considered for 
target volume definition for early or advanced rectal 
cancers. Target volumes contain at least the primary 
tumour, the mesorectal fat, presacral and internal iliac 
nodes.45 Given that patients in STAR-TREC will be clini-
cally node negative, the necessity of irradiating presacral 
and iliac nodes is questionable. Even in the case of unex-
pected nodal involvement, the majority of involved lymph 
nodes will be peritumoral in the mesorectum, as demon-
strated in a series of 121 patients with locally advanced 
rectal cancer who underwent CRT.46 The radiotherapy 
volume has therefore been reduced to the mesorectal 
fat only. To ensure safe introduction of this new tech-
nique, strict radiotherapy quality assurance is part of the 
protocol.
STAR-TREC is designed to achieve a recruitment rate 
that would provide confidence that extension into a phase 
III trial is achievable. Further applications for funding, 
ethics approval and a substantial protocol amendment 
would be required for this transition.
ConClusIon
There is an urgent need for a randomised phase III trial to 
establish the risks and benefits of organ saving compared 
with standard TME surgery for early-stage rectal cancer. 
STAR-TREC trial builds on experience gained through 
the TREC and CARTS phase II studies. STAR-TREC is 
a multicentre international randomised phase II study 
designed to assess the feasibility of recruiting six inter-
national patients per month in order to facilitate the 
evaluation of TME surgery versus organ-saving strategy 
preceded by (chemo)radiation in two different frac-
tionation schedules. The trial aims to improve the rate 
of patient recruitment compared with earlier studies 
and will also introduce a mesorectal target volume with 
quality assurance. The ultimate goal of this phase II feasi-
bility study is to accelerate to a phase III study comparing 
TME surgery with two organ-saving treatment regimens.
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